Anti-cancer drugs face a higher failure rate in clinical trials compared to other drugs, with approximately 95% of candidates not making it through the clinical trial phase. Existing methods fail to accurately simulate the human body, leading to unexpected results when transitioning to human trials.
Pre-Cure provides versatile and advanced Tumor-on-a-Chip and 3D cellular models, designed to improve cancer research and drug development.
Shift to 3D human cellular models that more accurately replicate human tissues, enhancing
diseasemechanisms and drugresponse studies
Mimicking the cancer microenvironment is crucial for understanding cancer progression and treatment resistance, capturing genetic diversity and cellular interactions within tumors
Reflect the dynamic nature of the human body by incorporating constant flow into
ex-vivo models, achieving gene expression that is closer to endogenous expression
Shift to 3D human cellular models that more accurately replicate human tissues, enhancing
diseasemechanisms and drugresponse studies
Mimicking the cancer microenvironment is crucial for understanding cancer progression and treatment resistance, capturing genetic diversity and cellular interactions within tumors
Reflect the dynamic nature of the human body by incorporating constant flow into
ex-vivo models, achieving gene expression that is closer to endogenous expression
Pre-Cure's platform incorporates a sophisticated Sensitivity Index, a powerful tool for quantifying and comparing drug efficacy across different cancer types, treatment options, multiple parameters, and killing assays. This index provides researchers with a standardized metric to evaluate the drug response.
Use an in-house 3D cellular model (organospheres) from cell lines of your choice or patient-derived
tumors to uncover the true essence of your research.
%201.png)
Please note the Pre-Cure™ test/drug screening platform is intended for use by licensed medical professionals for the purpose of information only. The report does not constitute a clinical diagnostic report, medical consultation or diagnosis, and does not constitute a substitute for professional consultation of a licensed healthcare entity. In addition, the report is not intended for use as a sole source of input for diagnosis, prognosis, or as the main basis for reaching a treatment decision, and the medical history should always be considered during any treatment decision making and on determining the best choice of treatment based on the experience and the clinical judgement of the treating physician. Any treatment decision remains the full responsibility of the treating medical entity. Pre-Cure does not take responsibility and does not promise the efficacy of any specific procedure, specific resources, specific tests, physician or other specific health service providers, specific drugs, specific biological preparations, specific medical instruments or other specific products, specific procedures, specific opinions, or other specific information which may be noted in the report.Pre-Cure does not promise and does not guarantee that any drug mentioned in the report will be efficient for treatment of the disease in any patient or does not promise or guarantee the effects that the drugs might have on the patient.The Pre-Cure™ test is carried out on fresh tissue received at the Pre-Cure laboratories within forty-eight (48) hours. Tissue samples are received and transferred under specific conditions, as required for analysis and reporting. Pre-Cure is responsible for coordination of tissue collection and delivery to Pre-Cure laboratories. The responsibility of tissue delivery is on the delivery company only. Pre-Cure makes great efforts in working with the delivery company in order to ensure that the tissue will arrive without unnecessary delay; however, Pre-Cure is not responsible for any delays.
Anti-cancer drugs face a higher failure rate in clinical trials compared to other drugs, with approximately 95% of candidates not making it through the clinical trial phase. Existing methods fail to accurately simulate the human body, leading to unexpected results when transitioning to human trials.
Pre-Cure provides versatile and advanced Tumor-on-a-Chip and 3D cellular models, designed to improve cancer research and drug development.
Shift to 3D human cellular models that more accurately replicate human tissues, enhancing
diseasemechanisms and drugresponse studies
Mimicking the cancer microenvironment is crucial for understanding cancer progression and treatment resistance, capturing genetic diversity and cellular interactions within tumors
Reflect the dynamic nature of the human body by incorporating constant flow into
ex-vivo models, achieving gene expression that is closer to endogenous expression
Shift to 3D human cellular models that more accurately replicate human tissues, enhancing
diseasemechanisms and drugresponse studies
Mimicking the cancer microenvironment is crucial for understanding cancer progression and treatment resistance, capturing genetic diversity and cellular interactions within tumors
Reflect the dynamic nature of the human body by incorporating constant flow into
ex-vivo models, achieving gene expression that is closer to endogenous expression
Pre-Cure's platform incorporates a sophisticated Sensitivity Index, a powerful tool for quantifying and comparing drug efficacy across different cancer types, treatment options, multiple parameters, and killing assays. This index provides researchers with a standardized metric to evaluate the drug response.
Use an in-house 3D cellular model (organospheres) from cell lines of your choice or patient-derived tumors to uncover the true essence of your research.
Please note the Pre-Cure™ test/drug screening platform is intended for use by licensed medical professionals for the purpose of information only. The report does not constitute a clinical diagnostic report, medical consultation or diagnosis, and does not constitute a substitute for professional consultation of a licensed healthcare entity. In addition, the report is not intended for use as a sole source of input for diagnosis, prognosis, or as the main basis for reaching a treatment decision, and the medical history should always be considered during any treatment decision making and on determining the best choice of treatment based on the experience and the clinical judgement of the treating physician. Any treatment decision remains the full responsibility of the treating medical entity. Pre-Cure does not take responsibility and does not promise the efficacy of any specific procedure, specific resources, specific tests, physician or other specific health service providers, specific drugs, specific biological preparations, specific medical instruments or other specific products, specific procedures, specific opinions, or other specific information which may be noted in the report.Pre-Cure does not promise and does not guarantee that any drug mentioned in the report will be efficient for treatment of the disease in any patient or does not promise or guarantee the effects that the drugs might have on the patient.The Pre-Cure™ test is carried out on fresh tissue received at the Pre-Cure laboratories within forty-eight (48) hours. Tissue samples are received and transferred under specific conditions, as required for analysis and reporting. Pre-Cure is responsible for coordination of tissue collection and delivery to Pre-Cure laboratories. The responsibility of tissue delivery is on the delivery company only. Pre-Cure makes great efforts in working with the delivery company in order to ensure that the tissue will arrive without unnecessary delay; however, Pre-Cure is not responsible for any delays.
All rights reserved - Precure 2024 | Website By Hex
